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Introduction
Chronic human immunodeficiency virus (HIV) infection in 
humans induces a serious damage in the gut, which leads to the 
loss of mucosal barrier integrity, microbial translocation, sys-
temic inflammation, and, in the end, to chronic immune activa-
tion.1–6 The use of combined antiretroviral therapy (cART) 
plays a fundamental role in the management of HIV-1 infec-
tion given its ability to suppress viremia, thus limiting the seed-
ing of viral reservoir7; furthermore, with the use of cART, 
HIV-1–positive patients are able to achieve a better health sta-
tus and prolonged longevity.7 However, antiretrovirals do not 
fully resolve systemic immune activation and inflammation; 
thus, HIV-1–infected subjects show an increased risk of devel-
oping various disorders and comorbidities, if compared with 
the general population.8 An intestinal dysbiosis exerting pro-
inflammatory effects has been frequently described among 
HIV-positive individuals9: the damage of the mucosal immune 
system can result in the modification of the usual gut-resident 
microbial community with the outgrowth of a “dysbiotic” 
microbial flora. This dysbiosis can affect the mucosal immune 
system, actively inducing an inflammatory microenvironment.
Along with the mucosal disequilibrium, alterations of the 
pathway of tryptophan metabolism, through a modification of 
the interferon-inducible enzyme indoleamine 2,3-dioxygenase 
1 (IDO-1) activity, have been described.10,11
Tryptophan, 1 of the 9 essential amino acids, cannot be syn-
thesized in humans and is usually obtained through dietary 
intake or released during protein turnover. This amino acid 
represents a critical component of several metabolic functions 
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ABSTRACT
BACkgRouNd: To date, no data are available regarding the effects of probiotics on the pathway of tryptophan/serotonin metabolism 
among human immunodeficiency virus (HIV) 1–infected individuals. Because a condition of dysbiosis might be responsible for the altered 
use of tryptophan described in this population, the aim of this study was to investigate the link between probiotic supplementation and sero-
tonin levels in combined antiretroviral therapy–treated patients and the subsistence of an interplay with inflammation.
MeTHodS: We conducted a pilot study that included 8 HIV-positive subjects. We collected blood and fecal samples before and after 
6 months of probiotic supplementation, to measure the level of serotonin in serum and tryptophan in stool, the expression of CD38 and HLA-
DR on peripheral CD4+ T lymphocytes (as immune activation markers), the expression of indoleamine 2,3-dioxygenase 1 messenger RNA 
(mRNA) and IFN-γ mRNA (as markers of tryptophan metabolism and systemic inflammation).
ReSulTS: After probiotic supplementation, we observed a significant increase in concentration of serum serotonin (P = .008) and a decreased 
level of tryptophan in plasma. Moreover, a significant reduction in CD38 and HLA-DR expression on the surface of peripheral CD4+ T cells 
(P = .008) and a reduced expression of indoleamine 2,3-dioxygenase 1 mRNA on peripheral blood mononuclear cells (P = .04) were observed.
CoNCluSIoNS: Considering that this probiotic (Vivomixx® in EU; Visbiome® in USA) has an influence on tryptophan metabolism, larger 
studies on this topic are needed.
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and can act as an important determinant of mood, cognition, 
and behavior.12,13 Tryptophan is used in the synthesis of pro-
teins and in the production of molecules such as the aminergic 
neurotransmitter serotonin (5-hydroxytryptamine [5-HT]) or 
nicotinamide adenine dinucleotide (NAD/NADH), via the 
kynurenine biosynthetic pathway. Kynurenine is the first stable 
metabolite to be synthesized when tryptophan is oxidized 
under the influence of l-tryptophan 2,3-dioxygenase, IDO-1, 
or IDO-2.14 Peripheral tryptophan levels in HIV-infected 
individuals are predominantly dependent on the activity of 
IDO-1,14–18 and studies have shown that the accelerated con-
version of tryptophan to kynurenine is correlated with an ele-
vation of levels of immune activation.
Probiotics have been proposed as a resource to counterbal-
ance the dysbiosis associated with liver,19 kidney,20 cardiovas-
cular,21 metabolic,22 and neurological disorders.23
We hypothesize that probiotic supplementation might exert 
an influence on tryptophan metabolism among HIV-1–
infected individuals through the correction of HIV-associated 
dysbiosis, resulting in an increase in serotonin levels. Because 
no data have been published to date on this topic, we per-
formed the first longitudinal pilot study to evaluate the impact 
of a high-concentration multistrain probiotic product on fecal 
levels of tryptophan, serum levels of serotonin, immune activa-
tion markers, and IDO-1 messenger RNA (mRNA) expres-
sion in peripheral blood mononuclear cells (PBMCs) of 
HIV-1–infected patients on effective cART.
Materials and Methods
Samples
Eight HIV-1–positive patients successfully treated with cART 
were recruited at the Division of Infectious Diseases, Department 
of Public Health and Infectious Diseases, Hospital of “Sapienza” 
University of Rome (Italy). The study was approved by the insti-
tutional review board (Department of Public Health and 
Infectious Diseases, “Sapienza” University of Rome and the 
Ethics Committee of Umberto I General Hospital, Rome). 
Inclusion criteria for this study were as follows: (1) signature of 
the written informed consent, (2) men or women at least 18 years 
old, (3) being on cART, and (4) presenting with HIV-1 RNA 
<37 copies/mL and CD4+ T counts >400 cells/mm3. Exclusion 
criteria were as follows: (1) known or suspected allergy or intol-
erance to study probiotic formulation, (2) use of probiotics or 
antibiotics during the 3 weeks prior the enrollment, (3) drug 
addiction, (4) history of or current inflammatory diseases of the 
small or large intestine, (5) diarrhea, (6) any current or previous 
systemic malignancy, and (7) pregnancy. Patients received a high 
concentration of lyophilized multistrain probiotic supplement 
twice a day for 6 months. The probiotic preparation contained 
1.8 × 1012 live bacteria/day (Lactobacillus plantarum DSM24730, 
Streptococcus thermophilus DSM24731, Bifidobacterium breve 
DSM24732, Lactobacillus paracasei DSM24733, Lactobacillus 
delbrueckii subsp bulgaricus DSM24734, Lactobacillus acidophilus 
DSM 24735, Bifidobacterium longum DSM24736, and 
Bifidobacterium infantis DSM24737) and is currently sold under 
the brand Vivomixx in Europe and Visbiome in the United 
States and Canada. All patients underwent blood and fecal sam-
ple collection prior to initiation (T0) and after 6 months (T6) of 
probiotic supplementation. No adverse event was observed dur-
ing the follow-up and all subjects maintained undetectable plas-
matic viral load before and after probiotic treatment.
Specimen processing
About 20 mL of whole blood was collected by venipuncture in 
Vacutainer tubes containing EDTA (BD Biosciences, San Jose, 
CA, USA) at each study visit. Peripheral blood mononuclear 
cells were separated by Ficoll gradient centrifugation 
(Lympholyte; Cedarlane Labs, Hornby, ON, Canada) and 
washed twice in phosphate-buffered saline solution.24 Freshly 
isolated PBMCs were used immediately for immune pheno-
typing and activation staining. About 10 mL of whole blood 
was collected by BD Vacutainer Plus Plastic Serum. After cen-
trifuge, serum was stored in aliquots at −80°C.
Bacterial DNA isolation from fecal samples
Bacterial DNA from fecal samples was extracted using the 
QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany). 
Approximately, 200 mg of feces were cut from frozen samples 
using sterile disposable scalpel, resuspended in 1.4 mL of ASL 
lysis buffer from the stool kit, added with glass beads (150-
212 µm; Sigma-Aldrich, St. Louis, MO, USA) and homoge-
nized thoroughly. The suspension was incubated at 95°C for 
5 minutes, and DNA was purified according to the manufac-
turer’s instructions. DNA was eluted in 200 µL of AE buffer 
(provided in the kit) and stored at −20°C.
Real-time polymerase chain reaction assay
Real-time polymerase chain reaction (PCR) was used to quan-
tify bifidobacteria using genus-specific primers and conditions 
described by Matsuki et al25 and to quantify the expression of 
IDO-1 and IFN-γ mRNA. Briefly, PCR amplification and 
detection were performed on optical-grade 96-well plates 
using the Applied Biosystems 7500 Real-Time PCR instru-
ment (Applied Biosystems Inc., Norwalk, CT, USA).
To quantify bifidobacteria, the reaction mixture (25 µL) was 
composed of SensiMix SYBR Low-ROX (Bioline, Taunton, 
MA, USA), 500-nM primers for Bifidobacterium genus and 
2.5 µL of template DNA. The fluorescent products were 
detected at the last step of each of 40 cycles. A melting curve 
analysis was made after amplification to distinguish the tar-
geted PCR product from the nontargeted PCR products. 
Standard curves were created using serial 10-fold dilutions of 
bacterial DNA extracted from B breve. All samples were ana-
lyzed in duplicate in 2 independent real-time PCR assays. For 
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IDO-1 and IFN-γ mRNA expression, total RNA was extracted 
from PBMC, using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) according to the man-
ufacturer’s protocol. The housekeeping gene β-glucuronidase 
was used as an internal control. Gene expression values were 
calculated by the comparative Ct method.26
T-cell phenotyping by flow cytometry
Phenotypes and activation markers were evaluated by Miltenyi 
Biotec flow cytometer-MACSQuant Analyzer (8 fluorescence 
channels, 3 lasers) on freshly isolated PBMC. Immune activa-
tion was evaluated by multiparameter flow cytofluorimetric 
analysis by the following antihuman monoclonal antibodies: 
CD3-PerCP, CD4-APC-Vio770, CD8-FITC, CD45RO-
PE-Vio770, CD27-VioBlue, CD38-APC, and HLA-DR-PE 
(Miltenyi Biotec, Bergisch Gladbach, Germany).
Enzyme-linked immunosorbent assay
Serum serotonin levels were detected by enzyme-linked immu-
nosorbent assay (ELISA) kit (Abnova, Taipei, Taiwan) based on 
an indirect assay with an antigen-antiserum bound and a conju-
gate antibody using a 3,3′,5, 5′-tetramethylbenzidine (TMB) as 
a substrate for the detection. For serotonin detection, we used an 
ELISA assay with an antiserotonin antibody precoated micro-
plate, a serotonin antiserum (rabbit antiserotonin antibody), a 
conjugate enzyme (goat antirabbit immunoglobulins conjugated 
with peroxidase), and a substrate for the reaction (containing 
tetramethylbenzidine, substrate buffer and hydrogen peroxide). 
The reaction was monitored at 450 nm. Quantification was 
achieved by comparing their absorbance with a reference curve 
prepared with known standard concentrations.
Virological analysis
Human immunodeficiency virus 1 RNA copy numbers were 
evaluated in plasma prepared from blood obtained in EDTA-
containing tubes and stored at −80°C. Levels of HIV-RNA 
were measured with Versant kPCR (Siemens Healthcare 
Diagnostic Inc., Tarrytown, NY, USA) with a detection limit 
of 37 copies/mL.
Fecal metabolome
Fecal samples were prepared for nuclear magnetic resonance 
(NMR) analysis by vortex mixing for 5 minutes 80 mg of 
stool with 1 mL of deionized water, followed by centrifuga-
tion for 15 minutes at 18 000g and 4°C. About 700 mL of 
supernatant was added to 100 µL of a D2O solution of 
3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid sodium salt, 
10 mM, set at pH 7.00 with 1-M phosphate buffer. Before 
analysis, the samples were again centrifuged.
Proton NMR (1H-NMR) spectra were recorded at 298 K 
with an AVANCE III spectrometer (Bruker, Milan, Italy) 
operating at a frequency of 600.13 MHz. The Hydrogen 
Deuterium Oxide (HOD) residual signal was suppressed by pre-
saturation, whereas broad signals from slowly tumbling molecules 
were removed by including a Carr-Purcell-Meiboom-Gill filter27 
to a free induction decay sequence. The filter was made up by a 
train of 400 echoes separated by 800 µs, for a total time of 328 ms. 
Each spectrum was acquired by summing up 256 transients using 
32 K data points over a 7211.54-Hz spectra (for an acquisition 
time of 2.27 seconds).The recycle delay was set to 8 seconds, 
keeping into consideration the longitudinal relaxation time of the 
protons under investigation. The so-obtained spectra were 
adjusted for baseline irregularities as explained elsewhere.28
The signals of tryptophan were assigned by comparing their 
chemical shift and multiplicity with Chenomx software data 
bank (ver. 8.1; Chenomx Inc., Edmonton, AB, Canada). The 
doublet signal at 7.747 ppm was finally used for molecular 
quantification because it was clear from interferences due to 
signals from different molecules.
Statistical analysis
Statistical analyses were performed using SPSS software, ver-
sion 22.00 (IBM, Somers, NY, USA) and R environment (ver-
sion 3.2.2; the R Foundation for Statistical Computing, 
Vienna, Austria) on data obtained from peripheral samples of 
HIV-1–positive patients before and after probiotic supplemen-
tation. Data obtained at T0 and T6 analysis in peripheral blood 
were compared by Wilcoxon test for paired samples.29,30 
Results, unless differently stated, were given as medians, ranges, 
and percentages. P values <.05 were considered statistically sig-
nificant. All graphs were generated using GraphPad Prism 
(version 5.00; GraphPad Software, Inc., La Jolla, CA, USA).
Results
Demographic and clinical characteristics of HIV-
1–positive patients
All study participants were HIV-1–positive white men with a 
median age of 42 (interquartile range [IQR]: 31-50) years old. 
Participants started cART during chronic HIV-1 infection and 
have been treated for a median of 6 years (IQR: 1.75-15.75). 
Probiotics were taken as a supplement to cART. The median of 
CD4+ cell count pre-cART was 255 cells/mm3 (IQR: 47.5-
360), and HIV-1 RNA median value was 5.0 log/mL (IQR: 
4.8-5.55). All subjects have been virologically suppressed (<37 
HIV-1 RNA copies/mL) for at least 1 year prior to enrollment; 
their median CD4+ cell count was 674.5 cells/mm3 before 
(IQR: 570.5-752.3) and 683 cells/mm3 (IQR: 587-796) after 
probiotic supplementation of cART.
Peripheral immune activation
We compared the immune activation of PBMCs measuring 
the levels of CD4 T cells expressing CD38 and HLA-DR 
markers, before (T0) and after probiotic supplementation (T6). 
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Our results showed a statistically significant reduction in the 
percentage of CD4+CD38+HLA−DR+ T cells at T6 (median: 
0.18 [IQR: 0.04-0.32]) compared with T0 (median: 0.80 
[IQR: 0.37-2.16]); P = .008 (Table 1).
IFN-γ mRNA
To assess systemic immune activation, we measured the levels 
of expression of IFN-γ mRNA in PBMCs, which is one of the 
main cytokines produced following CD4+ T-cell activation.
IFN-γ mRNA expression showed a reduction after 6 months 
of probiotic supplementation, without reaching statistical sig-
nificance (median: 8.60 [IQR: 2.06-23.80] vs median: 1.06 
[IQR: 0.32-2.97]) (P = .09) (Figure 1).
IDO-1 mRNA expression
We than analyzed whether 6 months of probiotic supplemen-
tation and the relative reduction in IFN-γ mRNA levels could 
affect the expression of IDO-1 mRNA in PBMCs. A signifi-
cant reduction in IDO-1 mRNA in PBMCs was observed at 
T6 (median: 0.0034 [IQR: 0.001-0.006]) compared with T0 
(median: 0.052 [IQR: 0.0024-0.18]) (P = .04) (Figure 2).
Tryptophan quantif ication
To assess whether the reduction in IDO-1 mRNA observed in 
PBMCs could affect tryptophan metabolism, we quantified 
tryptophan levels in fecal samples through metabolomic analy-
sis by 1H-NMR. A paired comparison revealed a significant 
decrease in tryptophan level between T0 and T6, as detailed in 
Table 2 (P = .031).
Levels of serotonin
To better understand the ongoing interrelation between probi-
otic supplementation, tryptophan metabolism, and neurocog-
nitive functions, we evaluated the modification of serotonin 
level in serum before and after probiotic intake. Our results 
showed a significant increase in the levels of serotonin at the 
end of supplementation (median: 185.3 ng/mL [IQR: 104.4-
292]) compared with baseline (median: 80.04 ng/mL [IQR: 
45.11-148.3]) (P = .008) (Figure 3).
Levels of bif idobacteria in stool
We assessed the amount of bifidobacteria in fecal samples at 
enrollment (T0), after 2 months (T2), and after 6 months 
(T6) of probiotic supplementation. We observed a signifi-
cant increase in this specific bacterial strain at T2 (P = .016) 
and T6 (P = .008) in comparison with T0 (Table 3). 
Bifidobacteria were included in the provided product and 
Table 1. Effect of probiotic supplementation in CD4+ T-cell immune 
activation.
PATIENTS CD4+CD38+HLA−DR+ T 
CELLS
CD4+CD38+HLA−DR+ T 
CELLS
T0* T6*
1 0.92 0.19
2 2.20 0.32
3 0.31 0.13
4 2.05 0.66
5 0.30 0.01
6 0.56 0.01
7 2.31 0.32
8 0.67 0.17
CD4+CD38+HLA−DR+ T-cell frequency before and after 6 months of probiotic 
supplementation in combined antiretroviral therapy (cART)–treated human 
immunodeficiency virus 1 (HIV-1)–positive patients with suppressed HIV-1 
viremia (n = 8). P value T0 vs T6 = 0.008.
*P < .05.
Figure 1. IFN-γ mRNA expression in PBMC. IFN-γ mRNA expression 
before and after 6 months of probiotic supplementation in PBMC of 
combined antiretroviral therapy–treated HIV-1–positive patients with 
suppressed HIV-1 viremia (n = 6) P > .05. HIV-1 indicates human 
immunodeficiency virus 1; mRNA, messenger RNA; PBMC, peripheral 
blood mononuclear cell.
Figure 2. IDO-1 mRNA expression in PBMC. IDO-1 mRNA expression 
before and after 6 months of probiotic supplementation in PBMC of 
combined antiretroviral therapy–treated HIV-1–positive patients with 
suppressed HIV-1 viremia (n = 8) *P = .04. HIV-1 indicates human 
immunodeficiency virus 1; IDO-1, indoleamine 2,3-dioxygenase 1; mRNA, 
messenger RNA; PBMC, peripheral blood mononuclear cell.
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this was assumed as an evidence of patient’s compliance with 
probiotic supplementation.
Discussion
The aim of this study was to evaluate the existence of a link 
between probiotic supplementation and the modification of 
serotonin levels in cART-treated patients and to clarify the 
role exerted by inflammation on this interplay. Moreover, 
through probiotic supplementation, we aimed to achieve 
among study population a reduction in systemic immune acti-
vation and its related inflammatory markers. To do so, we 
selected a high-concentration multistrain probiotic preparation 
with a known ability in modulating the expression of pro-
inflammatory cytokines such as tumor necrosis factor α, inter-
leukin 12, and IFN-γ in patients with inflammatory bowel 
diseases,31 inhibiting microbial pathogens growth by compet-
ing with them for epithelial colonization and in increasing 
tight junctions expression between enterocytes.32
In this study, the frequency of CD4+CD38+HLA−DR+ T 
cells resulted significantly decreased after 6 months of probiotic 
supplementation. The reduction in T-cell activation led to a 
decrease in the expression of the pro-inflammatory cytokine 
IFN-γ, although not reaching a statistical significance. Our 
results are in agreement with Ortiz et al who reported that in 
simian immunodeficiency virus–infected macaques, the same 
probiotic formulation, in combination with interleukin 21, 
reduced the expression of several markers of CD4+ T-cell 
immune activation, such as lipopolysaccharide-binding pro-
tein, antigen Ki-67, and soluble CD14 in PBMCs, bronchoal-
veolar lavage, jejunum ( Jej), lymph nodes, and rectal biopsies.33 
Similar results were published by Brenchley et  al34; in their 
study, these authors reported that CD4+ T-cell immune activa-
tion from colon samples resulted decreased after supplementa-
tion with high-concentration multistrain probiotic. The main 
hypothesis to explain these evidence is that the probiotic acts 
on toll-like receptors (TLR) signaling downmodulating TLR-
induced immune activation.35
Because we observed a reduction in the production of IFN-
γ and a beneficial effect on helper T 17 (TH17) cells induced by 
this probiotic, we measured the level of IDO-1 expression in 
PBMCs. According to literature, the activity of IDO-1 is 
influenced by IFN-γ and is associated with an imbalance in the 
TH17/regulatory T cells’ ratio36; moreover, its activity can exert 
divergent effects in immunosuppression or immunostimula-
tion in numerous conditions.37–39 Our results showed a reduc-
tion in the expression of IDO-1 mRNA in PBMCs after 
continuous probiotic supplementation for a period of 6 months, 
thus corroborating the hypothesis that IDO-1 represents the 
final player in the complex interaction between gut-resident 
flora, tryptophan metabolism, TH17 cells, and IFN-γ.
Finally, we observed a concurrent decrease in the levels of 
fecal tryptophan and an increase in serum serotonin levels after 
6 months of probiotic supplementation, although less than 1% 
of tryptophan is involved in the conversion to serotonin (5-HT) 
inside the brain.
In conclusion, in this study, we highlighted the evidence of 
a complex relationship between probiotic supplementation, 
inflammation, and serotonin levels in HIV-1–infected subjects 
treated with cART together with the safety of this high-
concentration multistrain probiotic in this population. This 
study presents several limitations such as the small size of the 
Table 2. Concentration of tryptophan in feces (mM/g) before and after 
6 months of probiotic supplementation in cART-treated HIV-1–positive 
patients with suppressed HIV-1 viremia (n = 8), P = .031.
PATIENTS T0 T6
(TRYPTOPHAN, MM/G) (TRYPTOPHAN, MM/G)
1 5.25 × 10−4 0.71 × 10−4
2 1.99 × 10−4 −0.1 × 10−4
3 0.60 × 10−4 0.15 × 10−4
4 1.78 × 10−4 1.88 × 10−4
5 4.3 × 10−4 6.18 × 10−4
6 1.09 × 10−4 0.66 × 10−4
7 2.06 × 10−4 0.84 × 10−4
8 2.37 × 10−4 0.30 × 10−4
P value T0 vs T6 = .031.
Figure 3. Serum serotonin levels. Serum serotonin levels before and 
after 6 months of probiotic supplementation in combined antiretroviral 
therapy–treated HIV-1–positive patients with suppressed HIV-1 viremia 
(n = 8). *P = .008. HIV-1 indicates human immunodeficiency virus 1.
Table 3. Bifidobacteria in fecal samples.
T0 VS T2 (P VALUE) T0 VS T6 (P VALUE)
Bifidobacteria/g of 
feces (log10)
.016 .008
Different amounts of bifidobacteria in fecal sample before (T0), after 2 months 
(T2), and after 6 months (T6) of probiotic supplementation in combined 
antiretroviral therapy–treated HIV-1–positive patients with suppressed HIV-1 
viremia (n = 8). The table shows the P value related to the significant differences 
observed.
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included sample, the lack of some tryptophan metabolites’ 
measurements (eg, plasmatic tryptophan and kynurenine), and 
the lack of an evaluation of the amount of IDO-1 protein and 
IDO-1 activity, the latter measured as kynurenine/tryptophan 
ratio (we only evaluated IDO-1 mRNA expression). If con-
firmed in subsequent studies, these data could strengthen the 
hypothesis that this specific probiotic formulation might influ-
ence tryptophan metabolism (Figure 4) and suggest novel 
treatment strategies to resolve or at least reduce some of the 
common disorders and symptoms observed among HIV-1–
infected patients effectively treated with cART.
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